The US FDA and the US Pharmacopeia may be at odds over biosimilar policies, but the two are trying to work together to encourage more small molecule generics to enter the market.
The organizations remain in the early stage of talks about how USP's monograph system could be used to generate more generic competition for drugs currently without competition, said Maryll Toufanian,...